Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A potentially registrational clinical trial to evaluate IMVT-1402 for treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Trial Profile

A potentially registrational clinical trial to evaluate IMVT-1402 for treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMVT-1402 (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 19 Mar 2025 According to an Immunovant media release, INDs active for both MG and CIDP with pivotal study initiations for lead asset IMVT-1402 in these indications expected imminently.
  • 05 Jun 2024 New trial record
  • 29 May 2024 According to an Immunovant media release, to optimize the level of disease activity and patient population for an IMVT-1402 clinical trial the company has decided to run the batoclimab CIDP trial approximately two quarters longer prior to unblinding period. Data from batoclimab CIDP trial will be used to optimize design of this trial prior to the end of the fiscal year (by March 31, 2025).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top